Search This Blog

Thursday, November 8, 2018

Lone U.S. Pot REIT Trounces Peers by Working Legal Gray Area

From the outside, the row of nondescript buildings in Hamptonburgh in upstate New York looks like any other U.S. warehouse complex. Inside, row after row of budding cannabis plants grow under bright lights and hundreds of security cameras.
The allure — and potential — of the marijuana industry has transformed the landlord, Innovative Industrial Properties Inc. into the best-performing U.S. real estate trust in the past 12 months. Shares rose as much as 5.3 percent Thursday in New York.
Innovative, America’s only publicly traded cannabis REIT, owns properties in eight states, where its tenants produce cannabis products. That makes it a high-reward, high-risk business — for the same reason.
Marijuana is classified as a Schedule I controlled substance by the federal government, the same as heroin, though it’s legal under state law everywhere Innovative operates. That often means growers can’t find space with regular landlords, so Innovative, with little competition, can charge higher rents.
“The interest keeps improving over time but we’re still technically breaking federal law,” Catherine Hastings, Innovative’s chief financial officer, said in an interview. “There’s a lot of institutional investors, when looking at their risk criteria, that are still hesitant to invest even though we’re on the New York Stock Exchange.”
None of that has deterred investors. Innovative has returned 117 percent in the last 12 months. It yields an average of 15.7 percent across its nine properties, according to a regulatory filing. And the San Diego-based company just had its fourth funding round in October, including its initial public offering, raising $119.6 million, with the bulk of that coming from retail investors.
Innovative is in a category all its own — it’s an industrial REIT — exempt from paying taxes as long as it passes most of its profits on to shareholders — that is also the only NYSE-listed REIT in the cannabis business.
Yet its regulatory filings are filled with the kind of risk warnings that would give pause to even the boldest investors. The company tells investors that the U.S. Justice Department could decide to go after cannabis-related businesses, or the Internal Revenue Service could question its REIT status, since the company hasn’t requested and doesn’t intend to request a ruling from the IRS on its REIT status, the company said in a filing.

Sessions Resigns

On Wednesday, the risks faced by Innovative grew a little more opaque. U.S. Attorney General Jeff Sessions resigned. Under Sessions — who once said “good people don’t smoke marijuana” — the Justice Department reversed a policy that made enforcement of pot laws a low priority. Sessions gave U.S. attorneys discretion on whether to go after medical marijuana producers. Pot stocks, already bolstered by wins in the midterm elections, rallied on Sessions’s departure.
President Trump installed Matt Whitaker, Sessions’s chief of staff, as acting attorney general — an official hardly considered weed-friendly. A former U.S. Attorney for the Southern District of Iowa, Whitaker cited his success “reducing the availability of meth, cocaine, and marijuana in our communities” in a resignation letter to President Barack Obama in 2009.
Yet for all those concerns, Innovative is also managing to help other businesses thrive.

Financing Troubles

For Vireo Health, a medical marijuana producer that operates out of an Innovative facility in Johnstown, New York, the company solved its financing difficulties.
“It’s not as if we could go into a commercial bank and get a mortgage on manufacturing facilities,” said Ari Hoffnung, Vireo Health’s chief executive. “Cannabis companies have to finance long-term assets with cash and that’s difficult and challenging for any business.”
The Vireo facility, on the site of the former Tryon Residential Center for Boys, which closed in 2010, is about 200 miles north of New York City. Innovative’s properties are also located in Arizona, Massachusetts, Maryland, Minnesota, Michigan, Colorado and Pennsylvania and it’s looking to enter California.

Michigan Referendum

On Tuesday, voters in Michigan, where Innovative is developing a facility for producer Green Peak Innovations, approved marijuana for recreational use. When Greek Peak hosted a job fair in October, it drew more than 500 applicants.
PharmaCann, which runs the 127,000-square-foot Hamptonburgh facility, said it spent $30 million to set up its business and comply with New York’s regulations.
Working with Innovative “allowed us to take that $30 million and recruit our director of research and development, to outfit the facility with equipment and develop processes that New York state accepts,” said Jeremy Unruh, PharmaCann’s director of public and regulatory affairs.
For now, Innovative’s investors are more focused on the company’s rewards than its risks.
“Given where traditional industrial properties trade today, which is let’s call it a third of that, it seems like the risk adjusted return is pretty attractive,” said Dirk Aulabaugh, managing director of Green Street Advisors. “You’re taking more risk and you’re earning a return that would be commensurate with that risk.”

Ligand selloff a ‘compelling accumulation opportunity,’ says H.C. Wainwright


H.C. Wainwright analyst Joseph Pantginis says the recent weakness in shares of presents a “compelling accumulation opportunity.” The investment case on Ligand is “unchanged” following its Q3 results, Pantginis tells investors in a research note. He views the selloff as “healthy,” noting the stock is “letting off of some steam after significant out-performance.” The analyst reiterates a Buy rating on Ligand with a $281 price target.

Henry Schein price target raised to $96 from $92 at Barrington


Barrington analyst Michael Petusky adjusted his 2019 EBITDA estimate for Henry Schein following the company’s mixed Q3 report and FY18 guidance affirmation, leading him to raise his price target on the shares to $96 from $92. He maintains an Outperform rating on Henry Schein shares, stating that he thinks the company’s efforts to reduce its cost structure and its increased focus on higher margin products should help it capture market share over time.

Meridian Bioscience Q4 Revenues Grow 7 Percent


Meridian Bioscience today reported a 7 percent year over year increase in its fiscal fourth quarter revenues and a 6 percent increase in fiscal year 2018 revenues.
For the quarter ended Sept. 30, the diagnostics manufacturer reported revenues of $53.1 million compared to $49.7 million in the prior year, beating analysts’ consensus estimate of $51.1 million.
Revenues from the firm’s Diagnostics segment grew 2 percent to $36.8 million from $36.0 million in the previous year, while revenues in the Life Science segment were up 19 percent to $16.2 million from $13.7 million.
“We are very pleased that those segments posted these levels of growth while executing efforts to integrate and streamline their respective commercial units,” said Meridian CFO Melissa Lueke during the firm’s a call to recap its earnings.
Leuke noted that the firm saw strong volume growth in respiratory illness assays with a 29 percent increase due to strength in Group A Strep and influenza assay sales. There was also a 12 percent increase in lead and blood chemistry assay sales due to increased penetration in pediatric offices leading to higher testing volumes. This growth was partially offset by declines in the gastrointestinal assays. Specifically, GI assays declined 5 percent primarily due to decline C. diff sales volume, offset by sales in H. pylori testing volume.
Meridian’s net earnings fell slightly to $5.4 million, or $.13 per share, from $5.7 million, or $.13 per share, in fiscal Q4 of 2017. On an adjusted basis, the firm reported earnings of $.20 per share, besting the consensus Wall Street estimate of $.16.
In fiscal Q4, Meridian’s R&D expenses was 19 percent lower year over year at $3.6 million compared to $4.5 million, while its SG&A expenses increased about 2 percent to $16.8 million from $16.5 million.
For fiscal year 2018, the firm’s revenues rose 7 percent to $213.6 million from $200.8 million in 2017, beating analysts’ consensus estimate of $211.7 million.
Revenues from the Diagnostics segment increased 5 percent to $150.5 million from $143.5 million in 2017, while revenues in the Life Science segment rose 10 percent to $63.1 million from $57.3 million.
The firm’s net earnings for the year fell to $23.8 million, or $.56 per share, from $21.6 million, or $.51 per share, in FY 2017. On an adjusted basis, the firm reported earnings per share of $.74, above Wall Street’s consensus estimate of $.70.
For FY 2018, R&D expenses rose 6 percent to $16.9 million from $16.0 million, while SG&A spending rose 9 percent to $69.0 million from $63.5 million.
The company ended the year with $59.8 million in cash and cash equivalents.
It also declared a regular quarterly cash dividend of $0.125 per share for the fourth quarter.
For fiscal 2019, Meridian provided guidance of 2 to 4 percent growth in net revenues and earnings per share of $.74 to $.76. Analysts, on average, are expecting revenues of $217.7 million and earnings per share of $.77 for 2019.

Takeda Launches Ulcerative Colitis Med in Japan


Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced the launch of Entyvio(R) (generic name: vedolizumab, development code: MLN0002) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan.
Takeda submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare (MHLW) in August 2017 based on the results from Study CCT-101, a Phase 3 clinical study including 292 Japanese patients with moderately to severely active UC alongside data from the global GEMINI 1 pivotal Phase 3 clinical study of vedolizumab induction and maintenance treatment involving 895 patients with moderately to severely UC.Takeda obtained the New Drug Application Approval in July 2018.
“Entyvio has been approved in more than 60 countries worldwide and has a robust clinical and real-world evidence base,” said Masato Iwasaki, Ph.D., President of the Japan Pharma Business Unit and Director of Takeda. “Takeda is pleased to provide healthcare providers and patients with an important new treatment option for ulcerative colitis and continue our mission of delivering innovative medicines for patients living with gastrointestinal diseases.”

Health insurers Centene, WellCare riding postelection wave


Health insurers are extending their postelection streak before the opening bell thanks to several ballot initiatives and the increased chance that a divided Congress that may not repeal the Affordable Care Act.
Shares of Centene Corp., WellCare Health Plans Inc. and Humana Inc., up between 7 percent and 9 percent this week, all edged higher in premarket trading, defying the broader markets which are retreating Thursday. The hospital chain HCA Healthcare Inc., up 5 percent for the week, is rising again.
Industry analysts believe congressional gridlock reduces the risk of major changes for the companies to deal with.
Voters in Idaho, Nebraska and Utah passed ballot measures to expand the federally and state funded Medicaid program. Centene and WellCare both devote large parts of their business to running Medicaid coverage.

Lonza: FDA OKs 1st Recombinant Factor C Assay for Endotoxin Testing


Lonza announced today that the recombinant Factor C (rFC) Assay has been used for endotoxin testing of Eli Lilly’s Emgality™ (galcanezumab), the first drug approved by the U.S. Food and Drug Administration (FDA) to have been released using this method instead of traditional Limulus Amebocyte Lysate (LAL) – based methods. Emgality™ is a monoclonal antibody drug treatment for the prevention of migraine in adults.
In 2003 Lonza launched the PyroGene™ recombinant Factor C Assay, the first endotoxin testing method to utilize a recombinant form of Factor C, the first component in the horseshoe-crab clotting cascade activated by the presence of endotoxins. As an animal-free method, the PyroGene™ Assay offers a more sustainable alternative to LAL-based tests that use the lysate obtained from horseshoe crab blood as their main ingredient.
‘The recent FDA approval of Emgality™ marks a significant breakthrough in establishing the recombinant Factor C Assay as the non-animal method of choice for the identification of contaminating endotoxins in drug products,’ said Lakiya Wimbish, Product Manager for Lonza’s PyroGene™ Recombinant Factor C Assay. ‘This development serves as an official confirmation that the recombinant Factor C method can be as accurate, sensitive and specific as LAL-based methods, while helping to secure the supply of natural resources.’
Allen Burgenson, Lonza’s Global Subject Matter Expert for Endotoxin Testing Solutions, said, ‘Lonza is the commercial innovator in bringing recombinant technology for endotoxin testing to market. This milestone accomplishment in advancing rFC technology will help to ensure the sustainability of the world’s horseshoe crab species. The three species of horseshoe crab found in Asia (Carcinoscorpius rotundicauda, Tachypleus tridentatus and Tachypleus gigas) are in serious decline due to overfishing, habitat loss and their use as a regional food. As these species become depleted due to a lack of regulatory oversight, countries such as China that use them to prepare Tachypleus Amebocyte Lysate (TAL) will look to the North American species, Limulus polyphemus, to fulfill their ever increasing needs in order to release non-pyrogenic pharmaceutical products to the market. Use of recombinant products, such as recombinant Factor C for endotoxin detection will greatly reduce the pressure on these species.’
More information about Lonza’s PyroGene™ Recombinant Factor C Assay is available on the Lonza website: www.lonza.com/pyrogene.